Edison Oncology at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

Edison Oncology brings 2 presentations to ENA 2026 in Barcelona. Its posters centre on its small-molecule drugs in early clinical development. They cover the safety and early activity of EO1001, an oral brain-penetrant pan-ErbB inhibitor, and the design of a phase I/II study of elesclomol (EO3001), a copper ionophore, stratified by ARID1A status.

Organization	ENA 2026 Attendance
Edison Oncology Menlo Park, CA
edisononcology.com Biotech Clinical-stage company developing small-molecule cancer drugs, including the brain-penetrant pan-ErbB inhibitor EO1001 and elesclomol.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents EO3001 (elesclomol), a copper ionophore that exploits ferredoxin-1 (FDX1) to drive cuproptosis in ARID1A-mutant solid tumors: preclinical rationale and design of an all-comer Phase I/II dose-escalation study with prospective ARID1A biomarker stratification Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Phase 1–2a Dose Escalation and Expansion of EO1001, an Oral Brain-Penetrant Pan-ErbB Inhibitor, in Advanced ErbB-Driven Solid Tumors: Safety, Pharmacokinetics, and Preliminary Clinical Activity Following Completion of Enrollment Targeted agents

Organization

ENA 2026 Attendance

Edison Oncology

Menlo Park, CA

edisononcology.com

Biotech

Clinical-stage company developing small-molecule cancer drugs, including the brain-penetrant pan-ErbB inhibitor EO1001 and elesclomol.

Poster

Thu Nov 19
9:30–10am
1–3pm
4:30–5pm

Part of Poster session: Molecular Targeted Agents

EO3001 (elesclomol), a copper ionophore that exploits ferredoxin-1 (FDX1) to drive cuproptosis in ARID1A-mutant solid tumors: preclinical rationale and design of an all-comer Phase I/II dose-escalation study with prospective ARID1A biomarker stratification

Targeted agents